Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #174265 on Biotech Values
oc631
02/15/14 12:42 AM
#174266 RE: oc631 #174265
GILD stands to lose many GT3 patients to the Sovaldi/Daclatasvir combination if approved.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads